Method for deficient bile replacement with external biliary drainage
SUBSTANCE: invention refers to medicine, namely to surgery, and describes a method for compensating a disturbed intestinal bile inflow in patients with the external biliary drainage. A method for the deficient bile replacement with the external biliary drainage consists in conducting a background therapy, prescribing a therapeutic formulation containing the following ingredients: ursodeoxycholic acid 12-15 mg/kg/day (up to 20 mg/kg) in 2-3 doses, Eslidin (soya lecithin phospholipids 300 mg; methionine 100 mg, soya oil up to 550 mg) 1 capsule 3 times a day at mealtimes; Milaif 0.2 g 3 times a day.
EFFECT: invention enables improving the patient's health condition and relieving a pain syndrome by a safe and technically easy method.
The invention relates to medicine, in particular to surgery, Oncology, and in particular to methods of treatment of obstructive jaundice in the pathology and blockage of bile ducts.
Treatment of patients with mechanical jaundice is the actual problem in surgery of the biliary tract. To reduce the manifestations of liver failure and endotoxemia this is admittedly one of the outer discharge of bile.
In violation of the bile passage even in cases of a partial (less than 500 ml per day) or complete cessation of its receipt in the intestine are marked disorders of digestion, absorption of products of digestion of fats and fat-soluble vitamins - a, D, E, K.
The outer discharge of bile, especially when long-term existence leads to an increase in energy costs hepatic synthesis of bile acids and profound disturbances of homeostasis due to violations of the enterohepatic circulation of bile.
Evidence of the effectiveness of the deficiency of bile, resulting from its loss, no doubt.
The literature describes a method of recovering recepter by collecting and extracorporeal purification of native bile (,And. Godovikov, L. A. igolkina, I. N. Klimovich. Theoretical background, rationale and factual information on the use of holesale alechenu hepatic failure in patients with mechanical jaundice // New technologies in surgical Hepatology: Mater. The third conference of surgeons-hepatologists. - SAT., 1995. - S. 416-417) with the subsequent return of her patient.
A similar method involves [the Application for the patent of the Russian Federation 94001617, AV 17/00, A61N 5/06] the return of bile after prior purification sorption on coal with ultraviolet irradiation and the addition of sodium hypochlorite solution.
In vitro clearance of bile along with the toxins removed a significant amount of bile acids, breaking their intestinal-hepatic circulation.
In addition, the conventional enteral route of administration through the mouth contains an element of estetichnosti hit, and bile in the stomach has ulcerogenic effect on the mucous membrane [Popov, A. N. et al. Syndrome Acholi in surgery of the biliary tract. Kazan: LLC "publishing house", 2003]. Oral bile is accompanied by inflammation of the gastric mucosa with the development of atrophic gastritis, negatively affects the production of hydrochloric acid [Kadyrov academies, Carotene T. A. Absorption of water, sodium chloride and glucose from the small intestine with prolonged loss of bile. In the book: Problems of physiology of human and animals in hot climates. Tashkent, 1965; 222-225].
As a prototype we have used the recovery Method of violations of the enterohepatic circulation of bile acids by the use of geodesics alevai acid" [Application for patent of the RF No. 98106092, AC 31/575, OR 1/16]. The way the prototype is as follows: patient prescribed drugs chenodesoxycholic acid at a dose of 10-30 mg/kg twice a day. Apply depending on the amount of loss of bile twice a day, starting 3 days of decompression during the whole period of the external discharge of bile.
However, the application of chenodesoxycholic acid is contraindicated in acute and chronic hepatitis, inflammatory diseases of the esophagus, stomach, intestine, malabsorption syndrome, liver and/or kidney failure, cholestatic syndromes and liver cirrhosis
The PURPOSE of the INVENTION
The goal of the proposed method consists in korregirovannye disturbed process of digestion and absorption of fats, resolution intrahepatic cholestasis, the suppression of bacterial overgrowth of intestinal bacteria, the restoration of the enterohepatic circulation of bile acids.
85-90% of total bile acids in bile - bile acids, which are involved in enterohepatic circulation.
Deficiency of bile acids in the intestine leads to decrease of bactericidal bile and excessive bacterial growth in the intestine, the violation of the hydrolysis of lipids, slow motility of the biliary system and intestines.
By finding the most effectiveimplementation to replace the bile, we assumed that adequate substitute is the use of tertiary bile acids, harmless to the body, and mixtures of lecithin with vitamin-amino acid-mineral composition.
In the available literature there are no reports of deficit reduction bile at its outer lead of these drugs.
Technical result is achieved by the proposed method, which includes the compensation of the deficit of bile through the proposed composition containing: ursodeoxycholic acid at a dose of 12-20 mg/kg/day in 2-3 doses, slidin 1 capsule 3 times a day during meals, milif 0.2 g×3 times a day.
With regular intake of the drug ursodeoxycholic acid is the main bile acid in plasma, accounting for about 48% of the total amount of bile acids in the blood. The drug significantly delays the progression of fibrosis, reduces the concentration of toxic bile acids, stimulates the production of pancreatic secretions and bile, has a hepatotropic immunomodulatory and antioxidant action.
As an important component of bile is phosphatidylcholine (lecithin), when the deficit reduction bile we decided the necessary connection of alidina (phospholipids from soya lecithin 300 mg, methionine 100 mg soybean oil, 550 mg).
The choice of drug milif (preparation plant about the convergence - biomass of mycelium monocultures of the fungus Fusarium sambucinum) due to the fact that the formula contains a complex of vitamins and trace elements, amino acids, fatty acids and has metabolic, tonic, adaptogenic, regenerating, detoxifying, hepatoprotective, immunomodulatory and antiviral action.
Drug milif registered health Ministry: registration certificate No. 97/292/9 from 03.10.1997,; P No. 000880/01-2001 from 06.12.2001,; No. 2000/260/1 from 14.07.2000, the Certificate of state registration №184.108.40.206..9505.8.05 from 18.08.2005, and # 220.127.116.11..9506.8.05 from 18.08.2005 was Patented in England, France, Germany, Switzerland, Liechtenstein, USA, Japan, and Russia.
EXAMPLES of CLINICAL APPLICATIONS
Example No. 1. Patient S., 72,, no history 2916. Hospitalized after 7 days after onset of the disease with complaints of pain in the right hypochondrium, yellowness of the skin. The state of admission heavy, the skin is intensely jaundiced. Bilirubin 223,4 µmol/L. ultrasound: gallbladder size 88×35 mm, wall thickness 6 mm, in a cavity defined concrements sizes up to 6 mm, 3-4 pieces, choledoch in diameter up to 10 mm, determine the concretions, 3 mm, 2 mm Pancreas size 36×16×16 mm
Clinical diagnosis of choledocholithiasis, complicated by mechanical jaundice. Concomitant diagnoses: coronary heart disease, atrial depict RDI, permanentny form, normokalemia. Gastritis.
In the dynamics noted the worsening condition of the patient, skin itching became more bilirubin 323,8 µmol/l Operated in case of emergency, imposed decompression holetsistitah. The amount of bile, separated by drainage for days 400-500 ml. Produced fistulography is determined by the extension of the choledochus up to 16 mm in the distal ureteral stones with a diameter of 10 mm
The patient in addition to primary treatment assigned, offered by us, medicinal composition containing: ursodeoxycholic acid 12 mg/kg/day in 3 divided doses, slidin 1 capsule 3 times a day during meals, milif 0.2 g × 3 times a day. At the same time was a moderate improvement in motor function of the intestine with the positive dynamics of biochemical indices of peripheral blood. The observed decrease skin itching, General weakness, the patient became active.
After reducing the numbers of total bilirubin up to 75 µmol/l produced retrograde papillosphincterotomy, remove stone choledochus. Obstructive jaundice resolved. On the control fistulography choledoch not expanded freely pass, contours precise, admission to 12-p. K-ku satisfactory. Due to the fact that there comorbidities and high-risk surgery, the patient is not made cholecystectomy. Cholecystectomies pipe is dropped. Written under the supervision of a surgeon of the clinic.
Example No. 2. Patient U., 62,, no history of the disease 437. Diagnosis: the disease of the choledochus, complicated by stricture and mechanical jaundice. Concomitant diagnoses: cicatricial narrowing of the anal canal, superficial gastritis.
- Ultrasound of the gall bladder is not increased, the wall thickness of 5 mm in the cervical area is defined hyperechoic education, not giving acoustic shadow, 1 cm in diameter, choledoch 7 mm Conclusion: the polyp of the gallbladder?
Performed studies gastroscopy, duodenoscopy, fluoroscopy of the stomach and duodenum 12 organic pathologies it is not revealed. Due to the fact that there was increase in mechanical jaundice, the patient performed cholecystostomy. Daily loss of bile 500-750 ml of the Patient in addition to primary treatment assigned, offered by us, medicinal composition containing: ursodeoxycholic acid 12 mg/kg/day in 3 divided doses, slidin 1 capsule 3 times a day during meals, milif 0.2 g × 3 times a day
After declining numbers of bilirubin patient operated - there is obstruction of the distal choledochus surround process and narrowing of the lumen. Performed the dissection of adhesions, cholecystectomy, resection of the choledochus and hepaticojejunostomy for Ru on the drainage. Was discharged in good condition.
Example No. 3. Patient E., 1981, № history 9362. The hospital is new in the Department of surgery within 2 days of onset with a diagnosis of acute cholecystitis. Ultrasound of the liver and bile ducts, gall bladder size 91×41 mm, wall thickness 4 mm, in the lumen of the concretions size of 0.1; 0.2; 0.3 cm - a lot. Choledoch 12 mm, the lumen of the concretions is not revealed. Clinical diagnosis: JCB complicated flegmonoznami calculous cholecystitis and mechanical jaundice. Concomitant diagnosis of urolithiasis.
Operation - cholecystostomy. The amount of bile, separated by drainage for the day - 300-400 ml. Patient treatment composition 3 times a day with 3 days after cholecystostomy. The level of bilirubin in the serum normalized on the 7th day, the motility of the bowel has recovered fully on the 4th day. On the control fistulography choledoch not expanded freely pass, contours precise, admission to 12-p. K-ku satisfactory. Was discharged in good condition.
The POSITIVE EFFECT of the application of the METHOD
Clinical trials of the proposed method of treatment of obstructive jaundice showed its significant advantages in comparison with applied in practice.
In the process of the treatment for 3-5 days marked improvement in the General condition of the patient, the weakening pain, reduce itching. Revived intestinal peristalsis, the chair was painted. Positive dynamics of biochemical indices of blood in the process tera is AI: the increase in the content of total protein, the reduction of bilirubin, ALT, ACT.
The method is safe, simple in technical execution and easily tolerated by patients. After receiving the proposed pharmaceutical composition noted:
regulation violated process of digestion and absorption of fats, as evidenced by the appearance of colored feces;
- recovery of intestinal peristalsis, eliminates constipation and flatulence, improves appetite;
- lack of development of allergic reactions;
- improvement of psychological status, improved mood, reduced headaches;
- stimulation suppressed the regenerative capacity of tissues.
The proposed method to overcome the lack of bile has advantages in that the components are non-toxic, have a hepatoprotective effect, contribute to the restoration portal and biliary circulation of bile acids and digestive processes.
Sources of information
- Zabazniy N. P., Maksymchuk Y. C., Collar C. A., Zhuravlev, M. N., Groshev I. A., Dobrynin O. C. // Abstraction of bile with high tumor obstruction of extrahepatic bile ducts. Russian cancer journal, 2007. No. 4. - S. 32-34.
- Kondracke Y., Kupcinskas L., Subscene I. Comparative evaluation of the effectiveness of ursodeauxiholeva acid (Ursofalk) and cholestyramine in the treatment of intrahepatic cholestasis is eremennyh. Results of a randomized trial // Gastroboletus. - 2001. No. 4. - S. 11-13.
- Yakovenko A. C., Yakovenko, E. P. cirrhosis of the liver: treatment issues // Gastroenterology. Volume 08/No. 7/2006.
- The method of treatment of violations of the enterohepatic circulation of bile in patients with external drainage of the biliary tract [Application for patent of the RF No. 98106092, AK 31/575, OR 1/16] - prototype.
The way to overcome the lack of bile to the outside of her recordings, including the introduction of drugs: ursodeoxycholic acid of 12-20 mg/kg/day in 2-3 doses, alidina 1 capsule 3 times a day during meals, mylife 0.2 g 3 times a day.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to a novel derivative of N-acylanthranilic acid, represented by the following general formula 1, or to its pharmaceutically acceptable salt, in which R1, R2, R3, X1, X2, X3, X4 and A are determined in the invention formula.
EFFECT: invention relates to an inhibitor of collagen production, a medication for treating diseases, associated with the excessive production of collagen, containing N-acylanthranilic acid derivative Formula 1.
SUBSTANCE: hepatoprotective agent based on a lipid fraction from an alcohol extract of perforated thallome ulva - Ulva fenestrate P. et R., containing less than 70% membrane-active lipid components, including not less than 20% essential phospholipids with content of polyunsaturated fatty acids of the n-3 series of not less than 55%.
EFFECT: agent has effective hepatoprotective action, speeds up restoration of stages of metabolic reactions, thereby providing normalisation of biochemical properties of carbohydrate and lipid exchange.
SUBSTANCE: hepatoprotector is used as peptide ACTH (4-7) -PGP (Semax) having the formula Met-Glu-His-Phe-Pro-Gly-Pro.
EFFECT: use of the said peptide with the aim of hepatoprotection under condition of the development of free-radical oxidation of hepatocytes enables to improve the efficiency of treatment of liver diseases accompanied by intensification of free radical oxidation processes.
1 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a new compound of formula [I] or to its pharmaceutically acceptable salt, wherein A represents optionally substituted alkyl, wherein the substitute represents identical or different 1-3 groups specified in aryl optionally substituted by 1-3 groups specified in alkyl, halogen, alkoxy and alkanoyl; cycloalkyl optionally substituted by 1-3 groups specified in alkyl and halogen; hydroxy; alkoxy; halogen; an amino group and oxo; an optionally substituted carbocyclic group specified in a mono- and bicyclic group, wherein an aromatic ring and cycloalkyl are condensed; optionally substituted aryl, an optionally substituted completely saturated 5- or 6-merous monocyclic heterocyclic group each of which contains 1 heteroatom specified in nitrogen and oxygen, wherein the substitute of optionally substituted aryl, the optionally substituted carbocyclic group and the optionally substituted heterocyclic group for A represents identical or different 1-3 groups specified in alkyl, optionally substituted hydroxy, alkoxy, cycloalkyl or halogen; cycloalkyl optionally substituted by alkyl or alkoxy; alkoxy optionally substituted by halogen; halogen; hydroxy; oxo; heterocycle; alkyl sulphonyl; and mono- or dialkylcarbamoyl, optionally substituted amino, wherein the substitute represents identical or different 1 or 2 alkyl or aryl, or optionally substituted carbamoyl, wherein the substitute represents identical or different 1 or 2 alkyls optionally substituted by aryl, X represents optionally substituted methylene or -O-, wherein the substitute of optionally substituted methylene for X represents alkoxy or hydroxy, Q represents N or C-R4, L1 represents a single bond, methylene, -CH=CH-, -O-, -CO-, -NR11-, -NR11CO-, -CONR11- or -CH2NR11-, L2 represents a single bond, -CR6R7- or a bivalent 5- or 6-merous completely saturated monocyclic heterocyclic group each of which contains 1 heteroatom specified in nitrogen and oxygen, R1 and R2 are identical or different, and each represents hydrogen, alkyl or halogen, R3 and R4 are identical or different, and each represents hydrogen, alkyl, alkoxy, cyano or halogen, R1 and R3 are optionally bond thereby forming 5- or 6-merous cycloalkane, or a 5- or 6-merous aliphatic heterocycle containing oxygen atom, R5 represents a carboxyl group, an alkoxycarbonyl group or a bioisosteric group of the carboxyl group, R6 and R7 are identical or different, and each represents hydrogen or alkyl, or R6 and R7 are bond thereby forming cycloalkane, R8 represents hydroxy, alkanoylamino or alkyl sulphonylamino, R9 and R10 represent hydrogen or halogen, and R11 represents hydrogen or alkyl. Besides, the invention refers to specific compounds of formula [I], a drug based on the compound of formula [I], using the compound of formula [I], a method of treating based on using the compound of formula [I], and an intermediate compound of formula [II].
EFFECT: there are prepared new compounds possessing the agonist activity on thyroid hormone β receptor.
18 cl, 36 tbl, 344 ex
SUBSTANCE: managing pregnancy in females suffering from overweight on their 26-30 weeks of pregnancy involves measuring an S-wave velocity in the hepatic tissue by acoustic pulse-wave elastometry. If an average value is 1.41 ms or more, hepatic protectors are administered.
EFFECT: reducing a rate of obstetric complications in the pregnant women suffering from overweight.
FIELD: veterinary medicine.
SUBSTANCE: method comprises complex pathogenetic therapy. Additionally, the specific biological preparation is used. The preparation is prepared according to the principle of production of cytotoxic serum from donor blood by hyperimmunisation of their antigens prepared from liver and spleen tissue. The antihepatotoxic serum and serum antisplenotoxic serum are obtained. They are mixed with sterile saline solution preserved with phenol to 0.5% concentration on the basis of the content in 1.0 ml of 0.9-1.15 its titrated units of antihepatotoxic and antisplenotoxic sera by reaction of binding the complement. The preparation is administered to animals once subcutaneously in the area of the withers at a dose of 0.45-1.1 ml per 1 kg of live weight. The method provides a higher immune status of the animal organism and high efficacy of treatment.
EFFECT: invention enables to improve the efficiency of treatment of liver steatosis in cats.
4 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a therapeutic agent for preventing and treating chronic liver diseases. The above agent represents amaranth oil prepared by cold pressing of amaranth seed kernels and coats, to be used in a dose of 62.5 - 250 mg/kg of body weight.
EFFECT: declared invention provides higher positive effect on biochemical processes in blood and liver tissues in treating toxic hepatitis.
SUBSTANCE: method involves simulating hepatitis by 7-day alcoholisation in female rats. A hepatoprotective agent is presented by an api-phytocomposition in the form of an aqueous suspension of honey, lecithin and licorice root extract in the ratio of 10:2:1. The composition is introduced twice a day intragastrically before feeding in a dose of 200 mg/kg of body weight 5 days before ethanol introduction and for 7 days one hour before ethanol introduction.
EFFECT: effective treatment of hepatitis with no side effects.
1 ex, 1 tbl, 1 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to a pharmaceutical, dietary, nutritional orally soluble composition for peroral intake, which contains at least one S-adenosylmethyonine (SAMe) salt in a combination with physiologically acceptable excipients and optionally other active ingredients. The physiologically acceptable excipients include light magnesium oxide.
EFFECT: compositions of the claimed invention have high taste qualities, which provides easier peroral introduction The compositions by the invention are characterised by the higher systemic bioavailability of S-adenosylmethyonine.
15 cl, 2 dwg, 13 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of pharmaceutics. An extract of Fraxinus excelsior seeds, capable of activating PPAR-alpha, which contains nuzhenide GI3, oleoside methyl ester, excelside B, GI5, salidroside, in effective quantities. An application of the extract of Fraxinus excelsior seeds to obtain a medication for treating a state, in which the PPAR-alpha activation is useful, is described. Also described is a method of treating a subject with the state, in which the PPAR-alpha activation is useful. A method of obtaining the extract of Fraxinus excelsior seeds is disclosed.
EFFECT: application of the claimed extract makes it possible to treat states, in which the PPAR-alpha activation is useful in an efficient way.
14 cl, 11 dwg, 2 tbl, 13 ex
SUBSTANCE: invention refers to veterinary science, and may be used for dog's hepatosis therapy. The method for dog's hepatosis therapy involves using a hepatoprotector, a microelement and herbal tea; the hepatoprotector is presented by the preparation Ursosan containing 250 mg of ursodeoxycholic acid; the microelement is selenium, and herbal tea is aqueous-alcoholic extract of camomile blossom clusters and birch buds used sequentially orally: Ursosan 10 mg per 1 kg of animal's body weight, selenium 3 mg per 1 kg of animal's body weight, aqueous-alcoholic extract of camomile blossom clusters and birch buds 1 ml per 1 kg of animal's body weight for 30 days every 12 hours.
EFFECT: method enables conducting the effective therapy and prevention of dog's hepatosis ensured by increasing liver resistance to unfavourable effects and an ability to recover the injured hepatic tissue, as well as by avoided allergic reactions on the administered hepatoprotector.
2 cl, 1 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, namely a method for preparing an agent for treating joints and managing muscular pain. A method for preparing an agent for treating joints and managing muscular pain, involving mixing hot pepper and oxgall, settling at room temperature, adding camphor spirit and settling at room temperature, and filtering under certain conditions.
EFFECT: agent prepared by the above method is effective for treating joints and managing muscular pain.
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to pharmaceutics and medicine and concerns an agent for treating locomotor diseases based on hot red pepper extract, preserved bile and camphor spirit prepared by a method characterised by the fact that hot red pepper 50-100 g is mixed with preserved bile 250-300 ml, kept for 1-2 days at room temperature, added with camphor spirit 250-300 ml, and kept for another 20-21 days at room temperature, and filtered.
EFFECT: invention is effective in osteochondrosis, arthroses, radiculitis, joint pains, tensions of ligaments, as well as in posttraumatic rehabilitation.
SUBSTANCE: invention is referred to the area of medicine. The remedy for treatment of kidney stone disease of urogenital system is the bile of poultry and game. The bile of healthy poultry or game can be using for treatment in any form, including raw fresh bile, solution containing certain dose of the bile, as a composition, containing food product, for example, honey, and raw fresh bile as a powder dissolved in the water, as tablets or capsules.
EFFECT: The invention will allow to increased number of products of non-chemical natural origin having increasing effectiveness for the treatment of kidney stone disease.
SUBSTANCE: invention is referred to the area of medicine and can be used for treatment of herpes hepatitis in children. The antiviral drugs prescribed included acyclovir (zovirax), valtrex, Isoprinosine, immunomodulatory drugs viferon, licopid, amixin, as well as ursodeoxycholic acid drugs, phosphogliv and viferon. Three different treatment protocols are used depending on the age. Doses, regimen and duration of exposure are established by protocols.
EFFECT: decreased terms of treatment; prevented development of complications; method can be used in out-patient setting.
SUBSTANCE: invention refers to medicine, particularly a method for treatment and prevention of nodular goiter. The method for treatment and prevention of nodular goiter involves administration of alcoholic tincture of bear bile with underlying standard treatment regimen.
EFFECT: method is effective for treatment and prevention of nodular goiter.
2 tbl, 1 ex
SUBSTANCE: invention relates to medicine and is intended for treatment of lingering versions of jaundice course in newborn babies. UDCA preparations are administered in dose 20-30 mg/kg per day, therapy is carried out for not less than 3 months. Viferon suppositories are administered rectally. Day dose is 50 thousand units/kg. Scheme of introduction is 10 days-daily, after that every second day from 3 to 9-12 months. Cytomegalovirus is suppressed with application of medication aciclovir-akri and its analogues zovirax, valtrex for 21-30 days. To suppress causing agents of mycoplasmosis, ureaplasmosis and chlamidiosis, preparations from group of macrolids rovamicin and sumamed are administered. Scheme is: rovamicin in dose 100 thousand units/kg for 7 days, after that, sumamed with a single dose 10 mg/kg once, according to discontinuous scheme 1 time per week, for 3 weeks. Additionally applied are medications, enhancing phagocytocis: licopid, polyoxydonium, solution of dimephosphone in age doses.
EFFECT: method makes it possible to reduce treatment terms and avoid complications.
SUBSTANCE: invention relates to medicine and is intended for treatment of gastroesophageal reflux disease (GERD) in patients with chronic opisthorchosis. PH-monitoring of upper parts of GIT and dehelmintisation are carried out. Type of reflux is determined. Preparations of ursodeoxycholic acid (UDCA) are administered. In case of mixed type of GER with prevalence of acid component dose is 250 mg/day for 2 weeks. In case of mixed type of GER with prevalence of alkali component dose is 500 mg/day before going to bed for 4 weeks. In isolated alkali version dose is 10 mg/kg in two intakes: morning and evening. In case of tgen pH>7 from 16.54 to 27.6%; NpH>7 from 27 to 31, and GER tgen pH>7 from 27.6 to 48.8%; NpH>7 from 31 to 35 - for 4 weeks. In case of tgen pH>7 from 16.54 to 27.6%; NpH>7 from 27 to 31, and GER tgen pH>7 from 27.6 to 48.8%; NpH>7 from 31 to 35 and in case of GER tgen pH>7 from 48.8 to 74.4%, NpH>7 from 36 to 42 - for 8 weeks. In case of tgen pH>7 from 48.8 to 74.4%; NpH>7 from 36 to 42, and GER tgen pH>7 from 16.54 to 74.4%; NpH>7 from 27 to 42 -for 12 weeks.
EFFECT: method makes it possible to reduce motor-tonic disturbances of biliary tract, reduce number of recurrences, enhance treatment efficiency.
4 cl, 5 ex
SUBSTANCE: invention concerns medicine, namely oncology, and can be used in treatment of unresectable biliary tract cancer complicated by obstructive jaundice. Substance of the invention consist that the patients underwent external biliary tract drainage, for the 10th postoperative day deliver bottled autobile 50 ml and 5-fluorouracil 500 mg. Then bottles are incubated during 40 minutes at 37°C. Further autobile with 5-fluorouracil is introduced into biliary tracts through stoma then to be blocked for 6 hours. Autobile chemotherapy into biliary tracts involves 10 sessions every second day.
EFFECT: application of the invention allows improving clinical effectiveness in the patients ensured by better patency of biliary tracts in direct antineoplastic action of 5-fluorouracil and lower toxicity of the method.
SUBSTANCE: substance of the invention consists in introduction of a complex of biologically active additives and plant preparation factors separately, sequentially between meals. Said biologically active additives include propolis in the form of 20% propolis butter, bear fat, seal fat and eicosavitol. The plant preparations are aspen bark tincture, arrowwood and cranberry water, vitamin herb tea combined with iodine-active and farina. Therapeutic course of the biologically active additives and plant preparations is 82-84 days.
EFFECT: lower acuteness of infectious process, optimisation of specific immune response on the complex of infectious agents ensured by higher antigen-binding capacity of antibodies.
3 cl, 8 tbl
SUBSTANCE: invention refers to veterinary science and can be used in integrated therapy of horses suffering from postpartum acute and chronic endometritis. A method for indirect endolymphatic therapy of endometritis in horses consists in lymphotropic administration of Lydase 64 IU dissolved in 0.25% Novocaine 1 ml and then a mixture consisting of polyoxidonium 6 mg, 0.25% Novocaine 100ml, oxytocin 30 IU and a daily unit of the antibiotic gentamicin by means of a universal device for intravenous infusion in the middle of the ischiorectal fossa at a depth of 1.5-2 cm twice every 48 hours.
EFFECT: method enables providing more effective treatment of endometritis in the horses, reducing a probability of side effects and recurrences, as well as cutting the length of treatment.